B. Riley Wealth Advisors Inc. Sells 101 Shares of Humana Inc. (NYSE:HUM)

B. Riley Wealth Advisors Inc. reduced its position in Humana Inc. (NYSE:HUM) by 12.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 712 shares of the insurance provider’s stock after selling 101 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Humana were worth $208,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Creative Financial Designs Inc. ADV lifted its position in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new stake in Humana during the 3rd quarter valued at $29,000. Hantz Financial Services Inc. bought a new position in Humana during the second quarter worth $35,000. Family Firm Inc. acquired a new position in shares of Humana in the second quarter valued at $37,000. Finally, Ashton Thomas Securities LLC bought a new position in shares of Humana in the third quarter valued at about $31,000. Institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on HUM shares. Royal Bank of Canada reduced their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Leerink Partners cut Humana from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. KeyCorp initiated coverage on Humana in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Stephens restated an “equal weight” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Finally, Piper Sandler lowered Humana from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $300.50.

Humana Price Performance

Humana stock opened at $247.10 on Friday. The company has a market capitalization of $29.75 billion, a PE ratio of 21.89, a P/E/G ratio of 2.15 and a beta of 0.53. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $273.79 and a two-hundred day moving average price of $320.62. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $475.00.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Analysts expect that Humana Inc. will post 16.14 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.43%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is presently 31.36%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.